Abstract:BACKGROUND:To assess potential roles for tumor-associated autoantibodies (TAAs) in esophageal squamous cell carcinoma (ESCC) screening: detecting early-stage malignancy, and predicting future cancer risk. METHOD:Thirteen candidate autoantibodies identified in previous literatures were measured using multiplex serological assays in sera from cases and matched controls nested in two population-level screening cohorts in China. To evaluate the role of TAAs in detecting prevalent esophageal malignant lesions, an identification set (150 cases vs. 560 controls) and an external validation set (34 cases vs. 121 controls) were established with pre-screening sera collected ≤ 12 months prior to screening-related diagnosis. To explore the role of TAAs in predicting future ESCC risk, an exploration set (105 cases vs. 416 controls) with pre-diagnostic sera collected > 12 months before clinical diagnosis was established. Two models, the questionnaire-based model and full model additionally incorporating TAA markers, were constructed. Area under the receiver operating characteristic curve (AUC) and net reclassification improvement (NRI) were calculated to compare the performance of the two models. FINDINGS:In the identification set, NY-ESO-1 (OR=2·12, 95% CI=1·02-4·40) and STIP1 (OR=1·83, 95% CI=1·10-3·05) were positively associated with higher risk of esophageal malignancy. Elevated MMP-7 was associated with higher risk of malignancy in females (ORfemale=5·07, 95% CI=1·30-19·71). The estimates in validation set were consistent with these results, but were close to null in exploration set. Integration of selected TAAs improved the performance of questionnaire-based models in detecting prevalent esophageal malignancy (female: AUCfull model=0·745, 95% CI=0·675-0·814, AUCquestionnaire-based model=0·658, 95% CI=0·585-0·732, NRI=0·604, P<0·0001; male: AUCfull model=0·662, 95% CI=0·596-0·728, AUCquestionnaire-based model=0·619, 95% CI=0·548-0·690, NRI=0·357, P=0·0028). This improvement was also seen in validation set, but was not similarly effective in distinguishing long-term incident cases from healthy controls. INTERPRETATION:Serological autoantibodies against NY-ESO-1, STIP1, and MMP-7 perform well in detecting early-stage esophageal malignancy, but are less effective in predicting future ESCC risks. FUNDING:This work was supported by the National Science & Technology Fundamental Resources Investigation Program of China (2019FY101102), the National Natural Science Foundation of China (82073626), the National Key R&D Program of China (2016YFC0901404), the Beijing-Tianjin-Hebei Basic Research Cooperation Project (J200016), the Digestive Medical Coordinated Development Center of Beijing Hospitals Authority (XXZ0204), and the Natural Science Foundation of Beijing Municipality (7182033).

Identification of novel tumor-associated antigens and evaluation of a panel of autoantibodies in detecting oral cancer

Identification of novel autoantibody signatures and evaluation of a panel of autoantibodies in breast cancer

A novel autoantibody signatures for enhanced clinical diagnosis of pancreatic ductal adenocarcinoma

Screening of tumor-associated antigens based on Oncomine database and evaluation of diagnostic value of autoantibodies in lung cancer

Using protein microarray to identify and evaluate autoantibodies to tumor‐associated antigens in ovarian cancer

Identification and Validation of Novel Serum Autoantibody Biomarkers for Early Detection of Colorectal Cancer and Advanced Adenoma.

Discovering Panel of Autoantibodies for Early Detection of Lung Cancer Based on Focused Protein Array

Identification of hepatocellular-carcinoma-associated antigens and autoantibodies by serological proteome analysis combined with protein microarray.

Development of a salivary autoantibody biomarker panel for diagnosis of oral cavity squamous cell carcinoma

Identification of Novel Autoantibodies Based on the Human Proteomic Chips and Evaluation of Their Performance in the Detection of Gastric Cancer

An Integrated Genome-Wide Approach to Discover Tumor-Specific Antigens As Potential Immunologic and Clinical Targets in Cancer

A Panel of Tumor-associated Autoantibodies for the Detection of Early-stage Breast Cancer

Diagnostic value of tumor associated autoantibody panel in early detection of lung cancer in Chinese population: Protocol for a prospective, observational, and multicenter clinical trial

Recent advances of neoantigen in tumor therapy

The application of autoantibodies detection in the early diagnosis and screening of lung cancer

Using Proteome Microarray and Gene Expression Omnibus Database to Screen Tumour-associated Antigens to Construct the Optimal Diagnostic Model of Oesophageal Squamous Cell Carcinoma

Immune landscape and subtypes in primary resectable oral squamous cell carcinoma: prognostic significance and predictive of therapeutic response

Circulating Tumor‐associated Autoantibodies As Novel Diagnostic Biomarkers in Pancreatic Adenocarcinoma

Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets

Tumor-associated Autoantibodies in ESCC Screening: Detecting Prevalent Early-Stage Malignancy or Predicting Future Cancer Risk?

Identification of Immune-Related Risk Signatures for the Prognostic Prediction in Oral Squamous Cell Carcinoma